Literature DB >> 7418718

A hand-held calculator program for individualized dosage adjustment of intravenous theophylline in acute asthma.

B W Madsen, R A Tarala, J W Paterson.   

Abstract

Despite general development of drug assay services and increasing interest in pharmacokinetics, proper dosage regimen calculations are not often made in routine clinical practice. This could be due, in part, to unfamiliarity with pharmacokinetic theory, the consequent difficulty of collaboration and the inevitable delay while data are processed on a computer. The present program for a hand-held calculator (TI-59) was written to minimize these problems, and was designed for the use of intravenous theophylline in the management of acute asthma, where there is a need for individualisation of dosage. Calculations are based on the one compartment open model. With 3--4 plasma drug concentrations taken early in the treatment, the program gives a measure of goodness of fit, the elimination rate constant (kel), the volume of distribution (Vd) and the suggested infusion rate to achieve a given steady-state level. Data from 10 severe acute asthmatic patients were used to test the model and the estimated parameters were: Vd = 0.26 +/- 0.029l/kg (mean +/- SEM) and Kel = 0.20 +/- 0.045 h(-1). The average standard deviation (s) for differences between the model and observations was 0.96 +/- 0.21 mg/l, of which at least 0.5 mg/l was due to assay error. In seven patients where the infusion period was extended, the predicted steady state plasma concentration agreed reasonably with that observed (r = 0.83, df = 5, 0.01 < p < 0.05).

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7418718     DOI: 10.1007/bf00558454

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  9 in total

1.  Kinetics of intravenous theophylline.

Authors:  F A Chrzanowski; P J Niebergall; R L Mayock; J M Taubin; E T Sugita
Journal:  Clin Pharmacol Ther       Date:  1977-08       Impact factor: 6.875

Review 2.  Clinical pharmacokinetics of theophylline.

Authors:  R I Ogilvie
Journal:  Clin Pharmacokinet       Date:  1978 Jul-Aug       Impact factor: 6.447

3.  Pharmacokinetics of intravenous theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

4.  Rational intravenous doses of theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  N Engl J Med       Date:  1973-09-20       Impact factor: 91.245

5.  Pharmacokinetics of theophylline. Application to adjustment of the clinical dose of aminophylline.

Authors:  J W Jenne; M S Wyze; F S Rood; F M MacDonald
Journal:  Clin Pharmacol Ther       Date:  1972 May-Jun       Impact factor: 6.875

6.  Significance of error associated with use of the one-compartment formula to calculate clearance of thirty-eight drugs.

Authors:  B H Dvorchik; E S Vessell
Journal:  Clin Pharmacol Ther       Date:  1978-06       Impact factor: 6.875

7.  Theophylline disposition in acutely ill hospitalized patients. The effect of smoking, heart failure, severe airway obstruction, and pneumonia.

Authors:  J R Powell; S Vozeh; P Hopewell; J Costello; L B Sheiner; S Riegelman
Journal:  Am Rev Respir Dis       Date:  1978-08

8.  Theophylline kinetics in acute pulmonary edema.

Authors:  K M Piafsky; D S Sitar; R E Rangno; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

9.  Theophylline disposition in obesity.

Authors:  P Gal; W J Jusko; A M Yurchak; B A Franklin
Journal:  Clin Pharmacol Ther       Date:  1978-04       Impact factor: 6.875

  9 in total
  2 in total

Review 1.  Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application.

Authors:  S Vozeh; J L Steimer
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

2.  A comparison of the accuracy of a least squares regression, a Bayesian, Chiou's and the steady-state clearance method of individualising theophylline dosage.

Authors:  S F Hurley; J J McNeil
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.